Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The association between aortic augmentation index and cardiovascular risk factors in a large unselected population

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The antihypertensive effect of fermented milk in individuals with prehypertension or borderline hypertension

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Increased ET(A) and ET(B) receptor contraction in the left internal mammary artery from patients with hypertension

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Frequency of obstructive sleep apnoea in Danish truck drivers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • C S Oxlund
  • C Cangemi
  • J E Henriksen
  • I A Jacobsen
  • J Gram
  • K Schousboe
  • L Tarnow
  • W S Argraves
  • L M Rasmussen
Vis graf over relationer

Diabetic patients with hypertension are at particularly high risk of vascular damage and consequently cardiovascular and renal disease. Fibulin-1, an extracellular matrix glycoprotein, is increased in arterial tissue and plasma from individuals with type 2 diabetes. This study aimed to evaluate whether antihypertensive treatment with spironolactone changes plasma fibulin-1 levels. In a multicenter, double-blind, randomized, placebo-controlled study, 119 patients with type 2 diabetes and resistant hypertension were included. A dose of spironolactone 25 mg or matching placebo was added to previous treatment at randomization. Blood pressure (BP) and plasma fibulin-1 were measured at baseline and at 16 weeks follow-up. Overall, 112 patients completed the study. All measures of BP were reduced in the spironolactone group at follow-up. Plasma fibulin-1 was significantly reduced after spironolactone treatment (P=0.009), but increased after placebo (P=0.017). Baseline plasma fibulin-1 correlated with BP and estimated glomerular filtration rate. Increased levels of plasma fibulin-1 (P=0.004) were observed in diabetic participants reporting erectile dysfunction as compared with participants who did not. Treatment with low-dose spironolactone reduced plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension. This supports the hypothesis that the antihypertensive effect of the mineralocorticoid receptor blocker in part may be due to regression of vascular remodeling.

OriginalsprogEngelsk
TidsskriftJournal of Human Hypertension
Vol/bind29
Udgave nummer1
Sider (fra-til)28-32
Antal sider5
ISSN0950-9240
DOI
StatusUdgivet - jan. 2015
Eksternt udgivetJa

ID: 44976073